OUR STORY

News and Reports

Ludwig scientists around the world are continually making discoveries that alter our understanding of cancer. Our science is featured in the most prestigious journals and in general media. Explore some of our most recent findings, news and reports.

For media inquiries, contact
Rachel Steinhardt
​Vice President of Communications

T 1 212 450 1582

Ludwig in the news

2016

Nov 10, 2016

GEN
Researchers led by Ludwig MSK's Taha Merghoub reported how a targeted drug can reverse the effects of certain immune cells that suppress responses to cancer immunotherapy. ​"We can now potentially identify patients whose tumors possess immune suppressor cells and add a drug to their treatment regimen to specifically disarm them," Merghoub tells GEN.

Jul 20, 2016

The Atlantic
A team co-led by Sangeeta Bhatia, researcher at Ludwig MIT, engineered strains of Salmonella bacteria to produce three types of cancer-killing drugs. The Atlantic reported on their findings, which show that, when used in combination with chemotherapy, the engineered bacteria can induce dramatic regressions of aggressive colon tumors.

Jul 20, 2016

Scope
A new Nature study co-authored by Irv Weissman, director of Ludwig Stanford, found that the “don’t eat me” signal many tumor cells display on their surfaces to evade immune system attack - called CD47 -  also appears to play a role in enabling atherosclerosis, the process underlying heart attacks and strokes. Stanford’s Scope blog explains the significance of these findings. 

Jul 11, 2016

GEN
Ludwig scientists speak about a blood-based screening test they’re developing to measure the a patient's risk of colon cancer recurrence after surgery and determine whether subsequent chemotherapy is advisable. "This study shows that when we find tumor DNA circulating in the blood of cancer patients, recurrence is very likely," says Nickolas Papadopoulos of Ludwig Johns Hopkins.

Jul 11, 2016

Cancer Research UK
Ludwig scientists have shown that fragments of tumor DNA circulating in the blood can be used to better gauge the risk of colorectal cancer recurrence and the necessity of chemotherapy following surgery. Cancer Research UK reports that these findings could one day help doctors to better monitor and tailor treatments for their patients.

Feb 24, 2016

MedCity News
Forty Seven, a clinical-stage immuno-oncology company founded by Ludwig Stanford director Irv Weissman, announced that it has completed the first half of a $75 million financing round and has licensed the rights to multiple immuno-oncology programs from Stanford University.

2015

Jun 15, 2015

GEN (free log-in required)

2014